News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
237,167 Results
Type
Article (5778)
Company Profile (20)
Press Release (231369)
Section
Business (87251)
Career Advice (465)
Deals (16468)
Drug Delivery (9)
Drug Development (21181)
Employer Resources (32)
FDA (4033)
Job Trends (4538)
News (129269)
Policy (8493)
Tag
Academia (332)
Africa (196)
Alabama (12)
Alliances (16067)
Alzheimer's disease (244)
Approvals (4024)
Arizona (41)
Artificial intelligence (7)
Asia (11884)
Australia (1566)
Bankruptcy (103)
Best Places to Work (3295)
Biosimilars (6)
Breast cancer (5)
C2C Services and Suppliers (27647)
California (234)
Canada (344)
Cancer (34)
Career advice (396)
Cell therapy (14)
China (5)
Clinical research (16935)
Collaboration (14)
Colorado (9)
Compensation (7)
Connecticut (8)
COVID-19 (426)
Cystic fibrosis (11)
Delaware (10)
Diagnostics (2123)
Diversity, equity & inclusion (13)
Drug pricing (6)
Earnings (40731)
Employer branding (6)
Employer resources (30)
Europe (24874)
Events (38754)
Executive appointments (14)
FDA (4043)
Florida (29)
Funding (10)
GLP-1 (85)
Government (510)
Healthcare (5490)
Hotbed/Location (177228)
Idaho (22)
Illinois (52)
Indiana (29)
Infectious disease (426)
Inflammatory bowel disease (19)
Interviews (57)
IPO (8244)
Job creations (1255)
Job search strategy (365)
Kansas (24)
Layoffs (100)
Legal (2695)
Liver cancer (12)
Maine (29)
Management (8)
Manufacturing (5)
Maryland (53)
Massachusetts (194)
Medical device (4192)
Medtech (4194)
Mergers & acquisitions (8141)
Metabolic disorders (16)
Michigan (5)
Neuroscience (256)
New Jersey (26)
New York (27)
NextGen Class of 2024 (1785)
Non-profit (782)
North Carolina (52)
Obesity (14)
Opinion (26)
Parkinson's disease (6)
Patents (5)
Pennsylvania (15)
People (25637)
Phase I (4996)
Phase II (7463)
Phase III (5822)
Postmarket research (660)
Preclinical (1995)
Rare diseases (14)
Real estate (2007)
Recruiting (9)
Regulatory (5416)
Reports (11)
Research institute (345)
Resumes & cover letters (68)
South America (303)
Startups (1120)
Texas (29)
United States (926)
Vaccines (18)
Washington State (22)
Webinars (5)
Weight loss (7)
Date
Today (19)
Last 7 days (153)
Last 30 days (581)
Last 365 days (13453)
2024 (7561)
2023 (14507)
2022 (20474)
2021 (21861)
2020 (19717)
2019 (14307)
2018 (11012)
2017 (10872)
2016 (10001)
2015 (13155)
2014 (10372)
2013 (8354)
2012 (9045)
2011 (9449)
2010 (9259)
237,167 Results for "apotex corp".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioMidwest
Apotex Corp. Launches Generic Fertility Treatment Injectable Cetrorelix® in the United States
Apotex Corp. announced the launch of Cetrorelix Acetate for Injection 0.25mg, a generic version of Cetrotide® in the United States.
May 14, 2024
·
1 min read
BioMidwest
Apotex Corp. Launches Teriparatide Injectable for Osteoporosis Treatment in the United States
Apotex Corp. announced the launch of Teriparatide Injection, a single-patient-use pre-filled pen used for the treatment of osteoporosis in the United States.
November 21, 2023
·
1 min read
Apotex to Participate in the Jefferies Global Healthcare Conference 2024
Apotex Inc. announced that Allan Oberman, President & CEO, will be presenting at the Jefferies Healthcare Conference on Wednesday, June 5th, 2024 at 9:00 am EST in New York, NY.
June 4, 2024
·
1 min read
Deals
Apotex to Acquire Searchlight Pharma, a Canadian Specialty Branded Pharmaceutical Leader
Canada’s largest pharmaceutical company, Apotex Inc. and Searchlight Pharma Inc. (“Searchlight”), one of Canada’s fastest growing companies, announced today that they have reached an agreement whereby Apotex will acquire Searchlight.
April 2, 2024
·
4 min read
Deals
Apotex Completes Acquisition of Searchlight, a leading Canadian-based Specialty Innovative Branded Pharmaceutical Company
TORONTO, June 3, 2024 /PRNewswire/ - Apotex Inc. announced the successful completion of its acquisition of Searchlight Pharma Inc., a leading Canadian specialty innovative branded pharmaceutical company.
June 3, 2024
·
2 min read
Apotex Inc. to Present at the 2024 Bloom Burton & Co. Annual Healthcare Investor Conference
Apotex Inc. announced today that Allan Oberman, President & CEO, will be presenting at the 2024 Bloom Burton & Co. Annual Healthcare Investor Conference on Wednesday, April 17th, 2024 at 11:30 am EST.
April 16, 2024
·
1 min read
Apotex Corp. Launches Brimonidine Tartrate Ophthalmic Solution, 0.1% in the United States
Apotex Corp. has released its latest ophthalmic product in the United States, announcing today that brimonidine tartrate ophthalmic solution, 0.1% is now available.
September 5, 2023
·
1 min read
Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
Harrow, Inc. and Apotex Inc. jointly announced an exclusive out-licensing agreement under which Apotex will market and distribute VERKAZIA® and over-the-counter Cationorm® PLUS in the Canadian market, and concurrently, pursue market approval in Canada for VEVYE®, IHEEZO®, and ZERVIATE®.
February 15, 2024
·
5 min read
Apotex Corp. Launches Bendamustine Hydrochloride Injection in the United States
Apotex Corp. has expanded its oncology product portfolio with the launch of Bendamustine hydrochloride injection in the United States.
April 26, 2023
·
1 min read
Protect Pharmaceutical Corp. Issues Corporate Update
Protect Pharmaceutical Corp.'s (OTC: PRTT) (“Company”) President, Ali Yildiz, provides its shareholders with the following informational update: “July 1, 2024 Dear Shareholders: The Company’s PCAOB audit for the fiscal year of 2023 is near completion.
July 1, 2024
·
4 min read
1 of 23,717
Next
